3

FORM 3 SUBMISSION

Company: Amylyx Pharmaceuticals, Inc.
Filed: January 6, 2022
Period of Report: January 6, 2022
Accession Number: 0000899243-22-001241

View Document ↗ View on SEC.gov ↗